Avalo Therapeutics, Inc. Common Stock (AVTX)
Avalo Therapeutics, Inc. (AVTX) is a biotechnology company focused on developing innovative therapies for immune-inflammatory and specialized conditions. The company leverages its expertise in immunology and inflammation to advance treatments aimed at improving patient outcomes in chronic and rare diseases.
Company News
Merus NV shares jumped 38.2% in pre-market trading after Genmab announced plans to acquire the company for $8 billion in an all-cash deal, adding breakthrough therapy Petosemtamab to its late-stage pipeline.
Avalo Therapeutics announced the appointment of Kevin R. Lind to its Board of Directors, bringing over 20 years of leadership experience in biotechnology and capital markets. Lind previously led Longboard Pharmaceuticals to a $2.6 billion acquisition and will support Avalo's development of AVTX-009 for hidradenitis suppurativa.
Here is how Annexon, Inc. (ANNX) and Avalo Therapeutics, Inc. (AVTX) have performed compared to their sector so far this year.
Are these myths about penny stocks true? The post Top 3 Myths About Trading Penny Stocks appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.